Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AHSCT as Initial Salvage for Primary Induction Failure AML
NCT02441803Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2015
- Primary completion
- Sep 2020
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of decitabine, clofarabine, idarubicin, cytarabine in acute myeloid leukemia (AML), sponsored by University of Texas MD Anderson Cancer Center. Started Sep 2015; status: completed.
02
Drugs
decitabineclofarabineidarubicincytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02441803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02441803.